Physician profile
Mark Schacht
NPI 1265577621
$5,971.46
in general payments reported to CMS, 2019-2025
42 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $608 · 2021: $919 · 2022: $761 · 2023: $588 · 2024: $1,092 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.56 |
| Education | $120.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,253.18 | 2019-2024 | Erleada, Akeega |
| Medline Industries LP | $825.00 | 2019 | |
| Sumitomo Pharma America, INC. | $453.95 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $403.82 | 2019-2025 | |
| Astellas Pharma US INC | $376.18 | 2019-2025 | Xtandi |
| Abbvie INC. | $358.22 | 2019-2024 | |
| Blue Earth Diagnostics | $312.67 | 2019-2024 | |
| Travere Therapeutics, INC. | $196.73 | 2019-2022 | |
| Axonics, INC. | $164.29 | 2021-2024 | Axonics, Bulkamid |
| Astrazeneca Pharmaceuticals LP | $158.28 | 2020-2025 | Imfinzi |
| Myovant Sciences INC. | $139.31 | 2021-2022 | |
| Urogen Pharma, INC. | $107.87 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $97.50 | 2019-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $93.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.45 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schacht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.